SCHEMBL1800360

SCHEMBL1800360

CSCCC1NC2(CCN(C(=O)CCC3CCCC3)CC2)N(Cc2ccccc2[N+](=O)[O-])C1=O

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.38
LMNA P02545 4/20 0.38
KDM4E B2RXH2 3/20 0.38
TDP1 Q9NUW8 1/20 0.38
ACHE P22303 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.36
MAPK1 P28482 1/20 0.36
USP19 O94966 2/20 0.35
KDM1A O60341 1/20 0.35
MAOB P27338 1/20 0.35
MAPT P10636 1/20 0.34
HIF1A Q16665 1/20 0.34
KMT2A Q03164 3/20 0.34
MEN1 O00255 2/20 0.34
TSHR P16473 1/20 0.34
MMP2 P08253 1/20 0.34
MMP9 P14780 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1800359 0.89 SIGMAR1 (0.41) ALDH1A1LMNAKDM4ETDP1ACHE
SCHEMBL1802615 0.89 ALDH1A1 (0.41) ALDH1A1LMNAKDM4ETDP1ACHE
SCHEMBL1801397 0.88 ACHE (0.39) ALDH1A1LMNAKDM4ETDP1ACHE
SCHEMBL1799397 0.85 LMNA (0.46) ALDH1A1LMNAKDM4EACHESMN1; SMN2
SCHEMBL1798457 0.82 ALDH1A1 (0.41) ALDH1A1LMNAKDM4EACHESMN1; SMN2
SCHEMBL1802738 0.81 ALDH1A1 (0.43) ALDH1A1KDM4ESMN1; SMN2MAPTKMT2A
SCHEMBL1801124 0.81 ENPP2 (0.44) ALDH1A1LMNAKDM4ETDP1SMN1; SMN2
SCHEMBL1802774 0.81 ALDH1A1 (0.46) ALDH1A1LMNAKDM4ESMN1; SMN2MAPT
SCHEMBL2993155 0.80 ACHE (0.35) ALDH1A1LMNAKDM4ETDP1ACHE
SCHEMBL1798991 0.80 ALDH1A1 (0.41) ALDH1A1LMNAKDM4ETDP1ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951815-B2 Substituted 1,4,8-triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2011-05-31 US claimed
EP-1730147-B1 SUBSTITUTED 1,4,8-TRIAZASPIRO[4,5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY GRUENENTHAL GMBH (DE) 2010-02-03 EP claimed
US-20070015784-A1 Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US claimed
US-7951815-B2 Substituted 1,4,8-triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2011-05-31 US disclosed
EP-1730147-B1 SUBSTITUTED 1,4,8-TRIAZASPIRO[4,5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY GRUENENTHAL GMBH (DE) 2010-02-03 EP disclosed
US-20070015784-A1 Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015784-A1 Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds SI, SSTR4, SLC10A2 ALDH1A1 2780/4885LMNA 3374/4885KDM4E 3667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.